Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 73
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Saleh Hadi Alharbi
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 61
Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes
Lindsey Wang, Nathan A. Berger, David C. Kaelber, et al.
Gastroenterology (2024) Vol. 167, Iss. 4, pp. 689-703
Open Access | Times Cited: 35
Mechanisms of long COVID and the path toward therapeutics
Michael J. Peluso, Steven G. Deeks
Cell (2024)
Open Access | Times Cited: 30
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 21
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
Peter Thornton, Valérie Reader, Zsofia Digby, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 388, Iss. 3, pp. 813-826
Open Access | Times Cited: 19
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Brain-wide cell-type-specific transcriptomic signatures of healthy ageing in mice
Kelly Jin, Zizhen Yao, Cindy T. J. van Velthoven, et al.
Nature (2025)
Open Access | Times Cited: 5
Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration
Kevin Allan, Julia H. Joo, S.J. Kim, et al.
Ophthalmology (2025)
Closed Access | Times Cited: 2
Enhancing Tetrahydrocannabinol’s Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011
Dinesh Thapa, Mohan Patil, Leon N. Warne, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 148-148
Open Access | Times Cited: 2
The Effect of Semaglutide and GLP-1 RAs on Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy
Nadia Abbass, Raya Nahlawi, Jacqueline K. Shaia, et al.
American Journal of Ophthalmology (2025)
Open Access | Times Cited: 2
GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Amira Guirguis, et al.
Brain Sciences (2023) Vol. 13, Iss. 11, pp. 1503-1503
Open Access | Times Cited: 37
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 12
Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis
Yi Pan, Tong Bu, Xia Deng, et al.
Endocrine (2024) Vol. 84, Iss. 1, pp. 1-15
Closed Access | Times Cited: 9
Mechanisms coupling the mTOR pathway to chronic obstructive pulmonary disease (COPD) pathogenesis
Ankita Goyal, Vishal Chopra, Kranti Garg, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access | Times Cited: 1
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
Jingjing Zhang, X. Ye, Xuesong Liu, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 1
Closed Access | Times Cited: 1
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Robert F. Kushner, Donna H. Ryan, John Deanfield, et al.
Obesity (2025)
Open Access | Times Cited: 1
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Yutong Zhou, Wendong Suo, Xinai Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115669-115669
Open Access | Times Cited: 19
Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome
Wenxiu He, Jiahe Wei, Xing Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Iryna Halabitska, Л. С. Бабинец, Valentyn Oksenych, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1630-1630
Open Access | Times Cited: 7
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets
Paschalis Karakasis, Panagiotis Theofilis, Panayotis K. Vlachakis, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 209-209
Open Access | Times Cited: 6
Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease
Merita Rroji, Goce Spasovski
Biomedicines (2024) Vol. 12, Iss. 3, pp. 657-657
Open Access | Times Cited: 5
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Angela Dardano, Cristina Bianchi, Monia Garofolo, et al.
Atherosclerosis (2024) Vol. 394, pp. 117560-117560
Closed Access | Times Cited: 5
Association Between Type 2 Diabetes Mellitus and Alzheimer's Disease: Common Molecular Mechanism and Therapeutic Targets
Aparna Chauhan, Sachin Dubey, Smita Jain
Cell Biochemistry and Function (2024) Vol. 42, Iss. 7
Closed Access | Times Cited: 5
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network
Mahmoud Nassar, Omar Nassar, Hazem Abosheaishaa, et al.
Journal of Endocrinological Investigation (2024)
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top